| ID | 1103 | |
| PMID | 21999821 | |
| Year | 2010 | |
| Sequence | CGLHPAFQC | |
| Name | TDA1 | |
| Length | 9 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Cyclic (C1-C9) | |
| Chirality | L | |
| Chemical Modification | None | |
| Origin of Peptide | De novo synthesis | |
| Nature of Peptide/Cargo | Anti-obesity treatment, Adipose tissue-targeting property and transdermal capacity | |
| Mechanism | The in-vitro experiments inferred that the TDA1 peptide ligand would have bifunctional properties that could first target the hair follicles for its transdermal route to access systemic circulation, and then target the visceral adipose tissue via specific recognition between TDA1 and adipocytes. | |
| Cargo Sequence/Structure | None | |
| Name of cargo | Not applicable | |
| Assay | Franz cell system | |
| Enhancer | None | |
| Properties of enhancer | Not applicable | |
| Concentration | 7 mL of PBS (pH 7.4) and 2 × 1011 PFUs of each individual phage candidate in 100 μL of PBS (pH 7.4) | |
| Incubation time | 1, 4, 8 hours | |
| Tissue permeability (value with units) | Appearing frequency in the analyzed peptide pool (%) 28/280 (10) | |
| Tissue Sample | Abdominal skin surface of male wistar rats | |
| Ex vivo/In vivo/In vitro | in vitro | |
| STRUCTURE |
| |
| SMILES | N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O) [C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O) [C@@H](NC(=O)[C@@H](NC(=O)CNC1=O)CC (C)C)Cc1nc[nH]c1)CCC2)C)Cc1ccccc1)CCC(=O)N)C=O | |